#### **BAUSCH** Health

**Date** 

## 2017 Register for email alerts. All Categories **Archive** Date 12/29/17 **Title** Valeant Announces Preliminary Resolution Of Allergan Shareholder Securities Litigation **Download PDF** 12/22/17 **Date Title** Bausch + Lomb Receives FDA Approval of LUMIFY™ - The Only Over-The-Counter Eye Drop With Low-Dose Brimonidine For The Treatment Of Eye Redness **Download PDF** Date 12/20/17 **Title** Valeant Completes Sale Of Sprout Pharmaceuticals Subsidiary To Former Shareholders Of Sprout Pharmaceuticals **Download PDF** 12/18/17 **Date Title** Bausch + Lomb Begins Distribution Of VYZULTA™ (latanoprostene bunod ophthalmic solution), 0.024% To U.S. Wholesalers **Download PDF**

12/15/17

#### **Title** Valeant And One Of Its Subsidiaries Announce Early Tender Results And Early Settlement Date For Cash Tender Offers For Senior Notes **Download PDF Date** 12/07/17 Title Valeant To Participate At The BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference **Download PDF** 12/04/17 **Date Title** Valeant Announces Pricing Of Private Offering Of Senior Notes **Download PDF** Date 12/04/17 **Title** Valeant And One Of Its Subsidiaries Announce Upsize Of Cash Tender Offers To \$1,500,000,000 **Outstanding Principal Amount Download PDF** 12/04/17 **Date Title** Valeant And One Of Its Subsidiaries Commence Cash Tender Offers For Up To \$1,000,000,000 Outstanding Principal Amount Download **PDF** 12/04/17 **Date Title**

Date	11/21/17

Valeant Announces Launch Of Private Offering Of Senior Notes

**PDF** 

**Download** 

## **Title** Valeant Announces Closing Of Add-On Secured Notes And Credit Agreement Amendment **Download PDF** 11/21/17 **Date Title** Valeant To Participate At The Evercore ISI Biopharma Catalyst/Deep Dive Conference Download **PDF Date** 11/15/17 **Title** Bausch + Lomb Helps To Recycle More Than One Million Units Of Contact Lens Materials Within First Year Of Launching The ONE By ONE Recycling Program **Download PDF** 11/14/17 **Date Title** Valeant Announces Pricing Of Private Offering Of Add-On Secured Notes **Download PDF** 11/14/17 **Date Title** Ortho Dermatologics Announces Aspire Higher Scholarship Honorees Download **PDF** 11/13/17 **Date Title** Valeant Announces Launch of Private Offering of Add-On Secured Notes **Download PDF** 11/10/17 **Date Title** Valeant Pharmaceuticals Completes Sale of Obagi Medical Products Business to Haitong International

Zhongua Finance Acquisition Fund I, L.P.

Download	PDF
Date	11/08/17
Title	
Valeant To Participate At The St	ifel 2017 Healthcare Conference
Download	PDF
Date	11/07/17
Title	
Valeant Announces Third-Quart	ter 2017 Results
Download	PDF
Date	11/06/17
Title	
Valeant Agrees To Sell Sprout P Pharmaceuticals	harmaceuticals Subsidiary To Former Shareholders Of Sprout
Download	PDF
Date	11/02/17
Title	
Bausch + Lomb And Nicox Announce FDA Approval Of VYZULTA™ (latanoprostene Bunod Ophthalmic Solution), 0.024%	
Download	PDF
Date	11/02/17
Title	
Ortho Dermatologics Announce Treatment	es U.S. FDA Filing Acceptance For IDP-118, Novel Plaque Psoriasis
Download	PDF
Date	10/31/17
Title	
Valeant Will Reduce Debt By Ac	dditional \$125 Million

Download	PDF
Date	10/16/17
Title	
Valeant And One Of Its Su Cash Tender Offers For Se	bsidiaries Announce Early Tender Results And Early Settlement Date For nior Notes
Download	PDF
Date	10/12/17
Title	
•	ounces Two-Year Findings From Pivotal Phase 3 Study Of SILIQ™ ata Demonstrating Long-Term Efficacy Profile
Download	PDF
Date	10/04/17
Title	
Solta Medical Receives FD Smoothing Technology	0A 510(k) Clearance for Thermage FLX™ System, Newest Generation Skin
Download	PDF
Date	10/03/17
Title	
Bausch + Lomb Introduce	s Biotrue® ONEday for Astigmatism Contact Lenses in Europe
Download	PDF
Date	10/03/17
Title	
Valeant Will Release Third	-Quarter 2017 Financial Results On November 7
Download	PDF
Date	10/02/17
Title	
Valeant Announces Pricin	g Of Private Offering Of Senior Secured Notes

Date	
	10/02/17
Γitle	
Valeant And One Of Its Su Dutstanding Principal An	ubsidiaries Commence Cash Tender Offers For Up To \$1,000,000,000 mount
Download	PDF
Date	10/02/17
Γitle	
/aleant Announces Laun	ch Of Private Offering Of Senior Secured Notes
Download	PDF
Date	09/29/17
Гitle	
√aleant Pharmaceuticals The Carlyle Group	Completes Sale Of iNova Pharmaceuticals To Pacific Equity Partners And
Download	PDF
Date	09/27/17
Γitle	
/aleant Pharmaceuticals Plans	Provides Update On Canadian Regulatory Filing About Future Financing
Download	PDF
Date	09/27/17
<b>Fitle</b>	
/aleant to Participate at t	the Deutsche Bank 25th Annual Leveraged Finance Conference
Download	PDF
Date	09/18/17
Γitle	
/aleant To Participate At	The Cantor Fitzgerald Global Healthcare Conference

Download	PDF
Date	09/18/17
Title	
Valeant To Participate At The Ca	antor Fitzgerald Global Healthcare Conference
Download	PDF
Date	09/15/17
Title	
Valeant Commits \$200,000 to S	upport Hurricane Relief Efforts
Download	PDF
Date	09/06/17
Title	
Valeant To Participate At The Mo	organ Stanley Global Healthcare Conference
Download	PDF
Date	09/05/17
Title	
Ortho Dermatologics Submits N Psoriasis Treatment IDP-118	New Drug Application To The U.S. Food And Drug Administration For
Download	PDF
Date	08/16/17
Title	
Valeant Receives FDA Confirma Tampa Facility	tion Of Voluntary Action Indicated (VAI) Inspection Classification For
Download	PDF
Date	08/09/17
Title	
Paulson & Co., Inc. Reiterates Co	onfidence In Valeant Strategy
Download	PDF

Date	08/08/17
Title	
Valeant Announces Second-Qu	arter 2017 Results
Download	PDF
Date	08/07/17
Title	
Valeant Pharmaceuticals Receiv Bunod Ophthalmic Solution, 0.0	ves Complete Response Letter from the FDA for Latanoprostene 024% NDA
Download	PDF
Date	07/27/17
Title	
Valeant Announces U.S. Launch	of SILIQ™ (brodalumab) Injection
Download	PDF
Date	07/17/17
Title	
Valeant Agrees To Sell Obagi Mo	edical Products Business
Download	PDF
Date	07/13/17
Title	
Valeant Announces Redemptio Amount Of Its Outstanding 6.75	n Of Remaining Approximately \$500 Million Aggregate Principal 5% Senior Notes Due 2018
Download	PDF
Date	07/10/17
Title	
Valeant Announces Q2 2017 Fin	ancial Results Date And Conference Call Details
Download	PDF
Date	07/10/17

Title Valeant Pays Down \$811 Milli Download	ion of Senior Secured Term Loans
Date	07/06/17
Title	
Bausch + Lomb Japan Laun	ches Bausch + Lomb AQUALOX® Contact Lenses
Download	PDF
Date	06/29/17
Title	
Valeant Pharmaceuticals Co	mpletes Sale Of Dendreon To Sanpower Group
Download	PDF
Date	06/28/17
Title	
Salix Announces Filing Acce Colonoscopies	ptance For Plenvu®* Next Generation Bowel Cleansing Preparation For
Download	PDF
Date	06/22/17
Title	
Bausch + Lomb Named Mos Year By Brandspark Internat	st Trusted Contact Lens Solution Brand In Canada For Second Consecutive cional
Download	PDF
Date	06/19/17
Title	
Valeant Appoints Arthur J. S Communications	hannon As Senior Vice President, Head Of Investor Relations And
Download	PDF
Date	06/19/17

<b>Title</b> John Paulson Joins Valeant Board Of Directors	
Download	PDF
Date	06/08/17
Title	
Valeant Announces Sale of iN	ova Pharmaceuticals for \$930 Million
Download	PDF
Date	05/31/17
Title	
Valeant Pharmaceuticals To F	Present At Financial Industry Conferences
Download	PDF
Date	05/22/17
Title	
Bausch + Lomb Introduces re	nu® Advanced Formula Multi-Purpose Solution
Download	PDF
Date	05/17/17
Title	
Statement Regarding Xifaxar	Intellectual Property Litigation
Download	PDF
Date	05/10/17
Title	
Valeant Pharmaceuticals To F	Present At Health Care Conferences
Download	PDF
Date	05/09/17
<b>Title</b> Valeant Announces First Qua	rter 2017 Results And Raises Full Year Adjusted EBITDA Guidance Range

**Download PDF** 05/08/17 **Date Title** Bausch + Lomb Announces PDUFA Date For New OTC Redness Reliever, Brimonidine Tartrate Ophthalmic Solution, 0.025% **Download PDF** 05/05/17 **Date** Title Valeant Announces Key Appointments In Dermatology And Corporate Communications Leadership Download **PDF** 05/03/17 Date **Title** Valeant Announces 2017 Annual Meeting Results **Download PDF Date** 05/01/17 **Title** Valeant Announces Additional Debt Reduction Of Approximately \$220 Million **Download PDF** 04/26/17 **Date** Title Bausch + Lomb Receives 510(k) Clearance From FDA For Vitesse™, The First And Only Hypersonic, Open-Port Vitrectomy System **Download PDF** 04/21/17 **Date** Title Valeant's Patient Access And Pricing Committee Announces Pricing For SILIQ™ (Brodalumab) As The Lowest Priced Injectable Biologic For Moderate-To-Severe Plaque Psoriasis

Download	PDF
Date	04/10/17
Title	
Valeant Pharmaceutical Financial Results Confer	ls Announces 2017 Annual Meeting Of Shareholders Webcast And Q1 2017 rence Call
Download	PDF
Date	04/06/17
Title	
Bausch + Lomb Receive Phacoemulsification Pla	s 510(k) Clearance From FDA For Stellaris Elite™ Next-Generation atform
Download	PDF
Date	03/30/17
Title	
Bausch + Lomb ULTRA®	for Astigmatism Contact Lenses Introduced
Download	PDF
Date	03/21/17
Title	
Valeant Completes Refir	nancing Transactions
Download	PDF
Date	03/20/17
Title	
Valeant Announces the	Early Results of Tender Offers for Its 6.75% Senior Notes Due 2018
Valeant Announces the  Download	Early Results of Tender Offers for Its 6.75% Senior Notes Due 2018  PDF
Download	PDF

**Download PDF** 03/15/17 **Date Title** Bausch + Lomb Introduces Biotrue® ONEday For Astigmatism Contact Lenses **Download PDF Date** 03/10/17 **Title** Valeant Receives Lender Consent For Refinancing And Amendment Of Credit Agreement **Download PDF** 03/10/17 **Date Title** Valeant Announces Upsizing Of Cash Tender Offer For Its 6.75% Senior Notes Due 2018 **Download PDF** 03/10/17 Date **Title** Valeant Announces Pricing And Upsize Of Private Offering Of Senior Secured Notes **Download PDF Date** 03/09/17 **Title** Valeant Announces Launch Of Private Offering Of Senior Secured Notes **Download PDF** 03/07/17 **Date Title** Valeant Commences Cash Tender Offer For Up To \$600,000,000 Outstanding Principal Amount Of Its 6.75% Senior Notes Due 2018 **Download PDF** 

Date	03/06/17
Title	
	ely \$1.1 Billion Pay Down Of Senior Secured Term Loans From ng And Amendment Of Credit Agreement
Download	PDF
Date	03/03/17
Title	
Valeant Pharmaceuticals Comp	letes Sale Of CeraVe, AcneFree And AMBI Skincare Brands To L'Oréal
Download	PDF
Date	03/01/17
Title	
Valeant Pharmaceuticals Correc	cts Misleading Report About Salix Investigation
Download	PDF
Date	02/28/17
Title	
Valeant Reports Fourth Quarter	And Full Year 2016 Financial Results And Provides 2017 Guidance
Download	PDF
Date	02/27/17
Title	
Valeant Announces Deploymer Opportunity	t Of Expanded Salix Sales Force To Capture Untapped Market
Download	PDF
Date	02/27/17
Title	
Bausch + Lomb And Nicox Resubmit US New Drug Application For Novel Glaucoma Candidate Latanoprostene Bunod	
Download	PDF
Date	02/23/17

## **Title** Obagi Medical Products Announces Collaboration With Suzan Obagi, M.D., And Nextcell Medical To Introduce New Line Of Products Download **PDF Date** 02/21/17 Title Valeant Pharmaceuticals And EyeGate Enter Into Licensing Agreement For EGP-437 Combination Product In Post-Operative Pain And Inflammation In Ocular Surgery Patients **Download PDF** 02/16/17 **Date Title** Valeant Receives FDA Approval Of SILIQ™ (Brodalumab) For Moderate-To-Severe Plaque Psoriasis Download **PDF** Date 02/13/17 **Title** Valeant Pharmaceuticals To Participate At Healthcare Conferences **Download PDF** 01/30/17 **Date Title** Valeant To Hold Conference Call To Present Fourth Quarter And Full Year 2016 Results And Announce 2017 Guidance **Download PDF Date** 01/10/17 **Title** Bausch + Lomb Launches Expanded Parameters For Bausch + Lomb ULTRA® For Presbyopia Contact Lenses **Download PDF**

01/10/17

**Date** 

Title

Valeant Pharmaceuticals Announces Results Of Second Phase 3 Study For Psoriasis Treatment IDP-118

**Download** 

PDF

**Date** 

01/10/17

**Title** 

Valeant To Sell CeraVe, AcneFree And AMBI Skincare Brands To L'Oreal For \$1.3 Billion

Download

PDF

Date

01/09/17

**Title** 

Valeant To Sell Dendreon To Sanpower Group For \$819.9 Million In Cash

**Download** 

PDF

**Date** 

01/04/17

**Title** 

Valeant Pharmaceuticals To Present At The 35th Annual J.P. Morgan Healthcare Conference

Download

PDF

**Date** 

01/04/17

**Title** 

Valeant Pharmaceuticals Announces Addition Of Richard U. DeSchutter To Its Board Of Directors

**Download** 

PDF

#### **Investor Inquiries**





<u>ir@bauschhealth.com</u> 877-281-6642

LEGAL NOTICE

**PRIVACY POLICY** 

514-856-3855 (Canada)

**EMAIL ALERTS** 

**EMAIL PAGE** 

Use of this site signifies your agreement to

RSS FEED

Media inquiries

<u>Corporate.communications@bauschhealth.com</u> 908-569-3692

the Legal Notice and Privacy Policy. ©2025 Bausch Health Companies Inc. All rights

reserved. MTB.0230.USA.18 V2.0

# CALIFORNIA RESIDENTS: <u>DO NOT SELL MY</u> <u>PERSONAL INFORMATION</u>

